COMMUNIQUÉ DE PRESSE publié le 15/11/2023 à 12:45, il y a 11 mois 23 jours NanoViricides Has Filed its Quarterly Report - NV-387 Broad-Spectrum Antiviral in Clinical Trials Has Additional Applications
COMMUNIQUÉ DE PRESSE publié le 14/11/2023 à 12:45, il y a 11 mois 24 jours Broad-Spectrum Antiviral NV-387 (NV-CoV-2) in Phase 1a/1b Clinical Trial is Highly Effective in an Animal Model for MPox and Smallpox Drug Development
COMMUNIQUÉ DE PRESSE publié le 16/10/2023 à 12:45, il y a 1 année NanoViricides, Inc. Has Filed its Annual Report: Broad-spectrum Antiviral NV-387 (NV-CoV-2) in Phase 1a/1b Clinical Trial is Highly Active Against Coronaviruses as well as RSV
COMMUNIQUÉ DE PRESSE publié le 12/10/2023 à 12:45, il y a 1 année NanoViricides, Inc. to Present at the Partnership Opportunities in Drug Delivery Conference in Boston on October 16, 2023 at 6:07pm ET
COMMUNIQUÉ DE PRESSE publié le 21/08/2023 à 12:45, il y a 1 année 2 mois The Phase 1a/1b Human Clinical Trial of NV-CoV-2, the Company’s Broad-Spectrum Antiviral Drug, is Progressing Successfully, Reports NanoViricides
COMMUNIQUÉ DE PRESSE publié le 11/07/2023 à 12:45, il y a 1 année 3 mois Company’s Broad-Spectrum Antiviral NV-387 Has Demonstrated Excellent Effectiveness in RSV in a Lethal Lung Disease Animal Model, Reports NanoViricides
COMMUNIQUÉ DE PRESSE publié le 06/07/2023 à 12:45, il y a 1 année 4 mois Clinical Trial of Broad-Spectrum Antiviral Drug NV-CoV-2 is Progressing Well, Says NanoViricides - NV-CoV-2 is Positioned to Fulfill Many Unmet Medical Needs
COMMUNIQUÉ DE PRESSE publié le 29/06/2023 à 12:45, il y a 1 année 4 mois NanoViricides Announces that Clinical Trials of Its Broad-Spectrum Antiviral Drug NV-CoV-2 Have Begun
COMMUNIQUÉ DE PRESSE publié le 31/05/2023 à 12:40, il y a 1 année 5 mois NanoViricides, Inc. to Present at the BIO International Convention in Boston on June 5th, 2023 at 3:15pm ET
COMMUNIQUÉ DE PRESSE publié le 16/05/2023 à 12:45, il y a 1 année 5 mois NanoViricides Has Filed its Quarterly Report - Clinical Trials of Broad-Spectrum COVID Drug About to Begin
Publié le 08/11/2024 à 12:32, il y a 2 heures 18 minutes Louis Hachette Group announces the publication of its Information Document for listing on Euronext Growth (Paris)
Publié le 08/11/2024 à 12:32, il y a 2 heures 18 minutes Louis Hachette Group annonce la publication de son Document d’Information en vue de sa cotation sur Euronext Growth (Paris)
Publié le 08/11/2024 à 12:15, il y a 2 heures 35 minutes Louis Hachette Group announces the publication of its Information Document for listing on Euronext Growth (Paris)
Publié le 08/11/2024 à 12:15, il y a 2 heures 35 minutes Louis Hachette Group annonce la publication de son Document d’Information en vue de sa cotation sur Euronext Growth (Paris)
Publié le 08/11/2024 à 08:00, il y a 6 heures 50 minutes DAMARTEX / Droits de vote bruts et réels 31 octobre 2024
Publié le 08/11/2024 à 14:45, il y a 5 minutes Tune in For a Livestream with CEO Evan Gappelberg on Wednesday November 13th, 12pm EST
Publié le 08/11/2024 à 14:00, il y a 50 minutes NOA Lithium Closes $912,596 1st Tranche of the $2.7 Million Non-Brokered Private Placement
Publié le 08/11/2024 à 14:00, il y a 50 minutes Ballpoint Marketing - Leader in Handwritten Mail - Acquires a Friendly Competitor: Robot Ink Marketing
Publié le 08/11/2024 à 13:30, il y a 1 heure 20 minutes Moderna Receives Health Canada Approval for RSV Vaccine for Adults Aged 60 Years and Older
Publié le 08/11/2024 à 13:05, il y a 1 heure 45 minutes Aton Announces Corporate and Operations Update
Publié le 08/11/2024 à 12:31, il y a 2 heures 19 minutes Original-Research: ORBIS SE (von GSC Research GmbH): Kaufen
Publié le 08/11/2024 à 12:25, il y a 2 heures 25 minutes freenet Executive Board formulates financial ambition until 2028 - EBITDA and free cash flow to grow significantly
Publié le 08/11/2024 à 12:11, il y a 2 heures 39 minutes PNE AG selected by the European Commission for funding a project to produce hydrogen
